Group 1 - The A-share pet economy sector showed strong performance at the beginning of trading, with Kangtai Medical rising over 14% [1] - Rainbow Group and Huisheng Biological both increased by over 5% [1] - Other companies such as Jiaotong Angli, Hasi Lian, Yiyi Co., and Guai Bao Pet also experienced gains [1]

Core Views - The breeding sector is experiencing improved supply-demand dynamics due to intensified policy regulation, with measures from the National Development and Reform Commission (NDRC) aimed at optimizing pig production capacity, which is expected to enhance CPI targets and stabilize pig prices [4][50] - The beef industry is undergoing significant supply reduction, with a deep cycle anticipated as the number of breeding cows declines sharply, leading to lower beef supply starting in the second half of 2025 [6][88] - Smart agriculture is benefiting from ongoing policy incentives and increased funding, with water conservancy investments projected to reach 1.4 trillion yuan in 2024, marking a 12.8% year-on-year increase [6][50] Breeding Sector - The breeding industry is seeing a favorable supply-demand balance, with policies aimed at controlling production capacity and improving profitability for leading companies such as Muyuan Foods and Wens Foodstuffs [4][50] - The profitability of self-breeding operations is stable, while external pig purchases show fluctuating profits, indicating a need for careful management of breeding strategies [20][25] - The average weight of pigs being slaughtered has decreased, which is expected to reduce supply pressure and potentially increase pig prices in the coming months [41][42] Beef Industry - The domestic beef supply is expected to decrease significantly due to a reduction in breeding cow numbers, with the industry mirroring the pre-2019 pig cycle in terms of supply adjustments [6][88] - The beef market is characterized by a long adjustment period from breeding to market, typically requiring 2-3 years, which complicates supply management [70] Smart Agriculture - The smart agriculture sector is poised for growth driven by government policies and funding, with a focus on modernizing irrigation systems and enhancing water management practices [6][50] - The market for smart agriculture is projected to expand significantly, with the government aiming to establish 13 million acres of efficient water-saving irrigation [6] Animal Health - The veterinary drug sector is experiencing a structural shift due to the implementation of new GMP standards, which are raising industry entry barriers and promoting consolidation among leading firms [51][66] - The veterinary raw material drug prices are entering a recovery phase after a prolonged downturn, with demand expected to rise as breeding profitability improves [53][66] Investment Recommendations - Key investment targets include Muyuan Foods, Wens Foodstuffs, and Jiusan Foods in the breeding sector, as well as Deyu Water Saving and Ruipu Biological in the smart agriculture and animal health sectors, respectively [4][66][67]

Market Overview - A-shares maintained a narrow fluctuation on July 16, with the Shanghai Composite Index closing at 3503.78 points, down 0.03% [1] - The Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points, respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1] Sector Performance - Financial stocks collectively declined, while the steel, non-ferrous metals, and coal sectors showed weakness [1] - The automotive supply chain stocks surged, with companies like Rongtai Co., Fuda Co., and Zhejiang Rongtai hitting the daily limit [1] - The innovative drug concept saw significant activity, with stocks like Guosheng Tang and Iwu Biotech rising approximately 16% [5][6] - The humanoid robot concept remained hot, with companies like Shangwei New Materials achieving a six-day limit increase [2][4] Notable Company Movements - Huadian New Energy, which debuted on the Shanghai main board, closed up 125.8%, reaching a market value of over 300 billion yuan at one point [1] - Weiyali, a Hong Kong-based electronic component distributor, saw its stock surge by 288% upon resuming trading, with an intraday increase exceeding 900% [1] Humanoid Robot Sector Insights - The humanoid robot industry is in its early stages, with significant growth expected in the next 3 to 5 years across various applications [4] - The current phase is described as the "dawn" of humanoid robot industrialization, with mass production and large-scale application becoming feasible [4] - Cost reduction is crucial for the widespread adoption of humanoid robots, and companies that master core component technologies are recommended for investment [4] Innovative Drug Sector Insights - The innovative drug sector experienced strong gains, with several companies hitting the daily limit [5][6] - The recent launch of the 11th batch of national drug centralized procurement is expected to impact the market, focusing on mature "old drugs" rather than innovative drugs [7] - The introduction of measures to support the high-quality development of innovative drugs indicates a growing role for commercial insurance in the healthcare system [7] Pet Economy Sector Insights - The pet economy concept gained traction, with companies like Weike Technology rising over 10% [8] - The pet food sector is viewed as a growing market with significant long-term growth potential, particularly for domestic brands [8]

Group 1 - The pharmaceutical e-commerce sector saw a rise of 2.00%, ranking 8th among concept sectors, with 124 stocks increasing in value [1] - Notable gainers included Rundu Co., Aosaikang, and Wanbangde, which reached their daily limit up, while Furuishi and Laimei Pharmaceuticals also performed well with increases of 9.55%, 8.48%, and 5.54% respectively [1] - The sector experienced a net inflow of 750 million yuan from main funds, with 83 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Rundu Co. led the net inflow with 145 million yuan, followed by Yipin Hong, Furuishi, and Zhongsheng Pharmaceuticals with net inflows of 98.68 million yuan, 83.98 million yuan, and 70.42 million yuan respectively [2] - In terms of net inflow ratio, Rundu Co. had a leading rate of 42.20%, followed by Zhejiang Zhenyuan and ST Huluwawa at 29.25% and 16.55% respectively [3] Group 3 - The pharmaceutical e-commerce concept had a total of 124 stocks rising, with significant contributions from stocks like Rundu Co. and Aosaikang, which both showed strong performance [1][2] - The overall market sentiment in the pharmaceutical e-commerce sector appears positive, as indicated by the substantial net inflows and the number of stocks experiencing gains [2][3]

证券代码：300871 证券简称：回盛生物 公告编号：2025-067 武汉回盛生物科技股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、获取补助的基本情况 武汉回盛生物科技股份有限公司（以下简称"公司"）于近日收到地方政 府相关部门发放的政府补贴收入 205.00 万元（分次发放），占公司最近一期经 审计归属于上市公司股东的净利润绝对值的 10.17%。具体情况如下： 4、风险提示和其他说明 上述政府补助数据未经审计。最终会计处理以及对公司 2025 年度损益的 影响须以年度审计机构审计结果为准，敬请广大投资者注意投资风险。 | 获得补助的主体 | 武汉回盛生物科技股份有限公司 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 收到补助的时间及金额 | 2025 年 | 4 | 月 | 30 | 日，31.60 | 万元 | | | 2025 年 7 | | 月 | 11 | 日，173.40 | 万元 | | 补助形式和金额 | | | | 现金 | ...

Core Viewpoint - The recent private placement application by Huisheng Biological has been accepted by the Shenzhen Stock Exchange, but it faces significant criticism regarding the low issuance price and lack of specific investment projects, raising concerns about the interests of minority shareholders [1][2][3]. Company Summary - Huisheng Biological, a veterinary drug company, has been experiencing declining net profits since its IPO in 2020, with net profit dropping from 150 million yuan to a loss of 20.16 million yuan [6]. - The company's revenue has been increasing, but the net profit has been negatively impacted by the cyclical nature of the livestock industry and poor performance of previous investment projects [6][7]. - The company’s gross margin has decreased from 37% to 16.33%, and net margin has fallen from 19.31% to -1.65% due to various factors including declining product prices and rising costs [6]. Financing Details - The private placement will issue shares at a price of 9.19 yuan, significantly lower than the current market price of 20.68 yuan, which is only 44% of the market price [2][3]. - The maximum number of shares to be issued is 26,123,301, which could increase the controlling shareholders' stake to 47.92% [2][3]. - The total amount raised from this financing could reach 250 million yuan, but it is intended solely for replenishing working capital, raising questions about the necessity of the financing [3][4]. Investment Project Performance - Previous investment projects have largely failed to meet expected returns, with three out of five projects from the 2020 IPO not achieving their projected benefits [3][4]. - The company has faced challenges with its production capacity utilization and pricing, particularly in the case of the new products launched [4][6]. Industry Context - The veterinary drug industry is highly cyclical, with demand closely tied to the profitability of livestock farming [7]. - In the first quarter of 2024, Huisheng Biological reported a revenue increase of 92.96% and a net profit increase of 371.23%, attributed to improved cash flow in the livestock sector [7]. - However, the recent decline in pig prices raises uncertainty about whether the industry has truly recovered from its low point [7].

Market Overview - The Shanghai Composite Index fell by 0.13% on July 9, with 17 out of the 28 sectors rising, led by Media and Agriculture, Forestry, Animal Husbandry, and Fishery, which increased by 1.35% and 0.65% respectively [2] - The sectors with the largest declines were Non-ferrous Metals and Basic Chemicals, which dropped by 2.26% and 0.85% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.536 billion yuan, with only three sectors experiencing net inflows: Media (1.055 billion yuan), Retail (864 million yuan), and Construction Decoration (40.34 million yuan) [2] - The Electronic sector saw the largest net outflow, amounting to 7.789 billion yuan, followed by Non-ferrous Metals with 5.412 billion yuan [2] Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The Agriculture, Forestry, Animal Husbandry, and Fishery sector rose by 0.65% despite a net capital outflow of 437 million yuan [3] - Out of 103 stocks in this sector, 40 stocks increased, with one hitting the daily limit, while 55 stocks declined [3] - The top three stocks with net inflows were Xinwufeng (31.4665 million yuan), Haida Group (28.3706 million yuan), and Juxing Agriculture (21.9941 million yuan) [3][4] Top Gainers and Losers in Agriculture, Forestry, Animal Husbandry, and Fishery - **Top Gainers**: - Xinwufeng: +0.65%, 4.20% turnover, 31.4665 million yuan inflow [4] - Juxing Agriculture: +0.76%, 4.49% turnover, 21.9941 million yuan inflow [4] - **Top Losers**: - Muyuan Foods: -3.27%, 1.81% turnover, 71.5922 million yuan outflow [5] - Guolian Aquatic Products: -1.76%, 8.74% turnover, 45.2607 million yuan outflow [5]

国浩律师（深圳）事务所 关于 武汉回盛生物科技股份有限公司 创业板向特定对象发行 A 股股票 之 法律意见书 深圳市深南大道 6008 号特区报业大厦 24、31、41、42 楼 邮编：518034 24/F、31/F、41/F、42/F, Tequbaoye Buliding, 6008 Shennan Avenue, Shenzhen, Guangdong Province 518034, China 电话/Tel: (+86)(755) 8351 5666 传真/Fax: (+86)(755) 8351 5333 网址/Website: http://www.grandall.com.cn 二〇二五年七月 为出具本法律意见书，本所律师声明如下： | 释 | 义 | 4 | | --- | --- | --- | | 第一节 | | 引言 6 | | 第二节 | | 正文 9 | | 一、本次发行的批准和授权 9 | | | | 二、本次发行的主体资格 9 | | | | 三、本次发行的实质条件 10 | | | | 四、发行人的设立 15 | | | | 五、发行人的独立性 16 | | | | 六、发 ...

6-1-1 审计报告第 1 页共 1 页 审 计 报 告 众环审字（2025）0102563 号 武汉回盛生物科技股份有限公司全体股东： 一、审计意见 我们审计了武汉回盛生物科技股份有限公司（以下简称"回盛生物"）财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 回盛生物 2024 年 12 月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经营成果和 现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于回盛生物，并履行了职业道德方面的其他责任。我们相信，我们获 取的审计证据是充分、适当的，为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本年财务报表审计最为重要的事项。这些事 项的应对以对财务报 ...

中信建投证券股份有限公司 关于 武汉回盛生物科技股份有限公司 向特定对象发行股票 之 上市保荐书 保荐人 二〇二五年七月 保荐人出具的上市保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人陈子晗、张兴华已根据《中 华人民共和国公司法》《中华人民共和国证券法》等法律法规和中国证监会及深 圳证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则 和行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 3-3-1 | 释 义 4 | | --- | | 一、发行人基本情况 6 | | （一）发行人概况 6 | | （二）发行人主营业务 6 | | （三）发行人主要经营和财务数据及指标 6 | | （四）发行人存在的主要风险 8 | | 二、发行人本次发行情况 14 | | （一）发行股票的种类和面值 14 | | （二）发行方式及发行时间 14 | | （三）发行对象及认购方式 14 | | （四）发行价格及定价原则 14 | | （五）发行数量 15 | | （六）限售期 15 | | （七）募集资金金额与用途 15 | | （八）本次向特定对象发行前公司滚存未分配 ...